Spine metastases in prostate cancer: Comparison of technetium-99m-MDP whole-body bone scintigraphy, [18F]choline positron emission tomography(PET)/computed tomography (CT) and [18F]NaF PET/CT

BJU International

Volumn 114, Issue 6, 2014, Pages 818-823

  Poulsen, Mads H ^a   Petersen, Henrik ^a   Høilund Carlsen, Poul F ^a   Jakobsen, Jørn S ^a   Gerke, Oke ^a   Karstoft, Jens ^a   Steffansen, Signe I ^a   Walter, Steen ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

bone metastases; Choline; Fluoride; PET CT; prostate cancer

Indexed keywords

FLUOROMETHYLCHOLINE F 18; MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; SODIUM FLUORIDE F 18; UNCLASSIFIED DRUG; CHOLINE; FLUOROMETHYLCHOLINE;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BONE SCINTISCANNING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; GAMMA CAMERA; GLEASON SCORE; HUMAN; INTERMETHOD COMPARISON; MALE; MALIGNANT NEOPLASTIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET-CT SCANNER; PREDICTIVE VALUE; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SPINE METASTASIS; VERY ELDERLY; WHOLE BODY BONE SCINTIGRAPHY; ANALOGS AND DERIVATIVES; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROSPECTIVE STUDY; PROSTATE TUMOR; RADIOGRAPHY; SCINTISCANNING; SECONDARY; SPINAL CORD TUMOR;

AGED; AGED, 80 AND OVER; CHOLINE; HUMANS; MALE; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; SPINAL NEOPLASMS; TECHNETIUM TC 99M MEDRONATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84903603073     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12599     Document Type: Article

References (28)

1. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71
2. Potosky AL, Legler J, Albertsen PC, et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000; 92: 1582-1592
3. Freedland SJ, Moul JW,. Prostate specific antigen recurrence after definitive therapy. J Urol 2007; 177: 1985-1991
4. Fossa SD, Lilleby W, Waehre H, et al. Definitive radiotherapy of prostate cancer: the possible role of staging lymphadenectomy. Int J Radiat Oncol Biol Phys 2003; 57: 33-41
5. Sivalingam S, Oxley J, Probert JL, Stolzenburg JU, Schwaibold H,. Role of pelvic lymphadenectomy in prostate cancer management. Urology 2007; 69: 203-209
6. Giovacchini G, Picchio M, Coradeschi E, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010; 37: 301-309
7. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 572-583
8. Schirrmeister H, Glatting G, Hetzel J, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 2001; 42: 1800-1804
9. Engelhard K, Hollenbach HP, Wohlfart K, von Imhoff E, Fellner FA,. Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol 2004; 14: 99-105
10. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I,. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006; 47: 287-297
11. Almuhaideb A, Papathanasiou N, Bomanji J,. 18F-FDG PET/CT imaging in oncology. Ann Saudi Med 2011; 31: 3-13
12. Emonds KM, Swinnen JV, Mortelmans L, Mottaghy FM,. Molecular imaging of prostate cancer. Methods 2009; 48: 193-199
13. Bouchelouche K, Tagawa ST, Goldsmith SJ, Turkbey B, Capala J, Choyke P,. PET/CT imaging and radioimmunotherapy of prostate cancer. Semin Nucl Med 2011; 41: 29-44
14. Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I,. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis 2012; 15: 45-55
15. Even-Sapir E, Mishani E, Flusser G, Metser U,. 18F-Fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med 2007; 37: 462-469
16. DeGrado TR, Coleman RE, Wang S, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001; 61: 110-117
17. Hawkins RA, Choi Y, Huang SC, et al. Evaluation of the skeletal kinetics of fluorine-18-fluoride ion with PET. J Nucl Med 1992; 33: 633-642
18. Kryza D, Tadino V, Filannino MA, Villeret G, Lemoucheux L,. Fully automated [18F]fluorocholine synthesis in the TracerLab MX FDG coincidence synthesizer. Nucl Med Biol 2008; 35: 255-260
19. Teras M, Tolvanen T, Johansson JJ, Williams JJ, Knuuti J,. Performance of the new generation of whole-body PET/CT scanners: discovery STE and discovery VCT. Eur J Nucl Med Mol Imaging 2007; 34: 1683-1692
20. DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE,. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 2002; 43: 92-96
21. Venkitaraman R, Cook GJ, Dearnaley DP, et al. Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer. J Med Imaging Radiat Oncol 2009; 53: 241-247
22. Suva LJ, Washam C, Nicholas RW, Griffin RJ,. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol 2011; 7: 208-218
23. Brenner AI, Koshy J, Morey J, Lin C, DiPoce J,. The bone scan. Semin Nucl Med 2012; 42: 11-26
24. Poulsen MH, Bouchelouche K, Hoilund-Carlsen PF, et al. [18 F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients. BJU Int 2012; 110: 1666-1671
25. Withofs N, Grayet B, Tancredi T, et al. (1)(8)F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun 2011; 32: 168-176
26. Beheshti M, Vali R, Waldenberger P, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 2008; 35: 1766-1774
27. Langsteger W, Balogova S, Huchet V, et al. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. Q J Nucl Med Mol Imaging 2011; 55: 448-457
28. Kjölhede H, Ahlgren G, Almquist H, et al. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. BJU Int 2012; 110: 1501-1506